[go: up one dir, main page]

GB0510770D0 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
GB0510770D0
GB0510770D0 GB0510770A GB0510770A GB0510770D0 GB 0510770 D0 GB0510770 D0 GB 0510770D0 GB 0510770 A GB0510770 A GB 0510770A GB 0510770 A GB0510770 A GB 0510770A GB 0510770 D0 GB0510770 D0 GB 0510770D0
Authority
GB
United Kingdom
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0510770A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kudos Pharmaceuticals Ltd
Original Assignee
Kudos Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kudos Pharmaceuticals Ltd filed Critical Kudos Pharmaceuticals Ltd
Priority to GB0510770A priority Critical patent/GB0510770D0/en
Publication of GB0510770D0 publication Critical patent/GB0510770D0/en
Priority to JP2008512926A priority patent/JP2008542253A/en
Priority to PCT/GB2006/001946 priority patent/WO2006126010A2/en
Priority to EP06744013A priority patent/EP1895997A2/en
Priority to US11/915,282 priority patent/US20090035394A1/en
Ceased legal-status Critical Current

Links

GB0510770A 2005-05-26 2005-05-26 Cancer treatment Ceased GB0510770D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB0510770A GB0510770D0 (en) 2005-05-26 2005-05-26 Cancer treatment
JP2008512926A JP2008542253A (en) 2005-05-26 2006-05-26 Use of DNA-PK inhibition to sensitize ATM-deficient cancer against DNA-damaged cancer therapy
PCT/GB2006/001946 WO2006126010A2 (en) 2005-05-26 2006-05-26 Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies
EP06744013A EP1895997A2 (en) 2005-05-26 2006-05-26 Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies
US11/915,282 US20090035394A1 (en) 2005-05-26 2006-05-26 Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0510770A GB0510770D0 (en) 2005-05-26 2005-05-26 Cancer treatment

Publications (1)

Publication Number Publication Date
GB0510770D0 true GB0510770D0 (en) 2005-06-29

Family

ID=34834688

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0510770A Ceased GB0510770D0 (en) 2005-05-26 2005-05-26 Cancer treatment

Country Status (1)

Country Link
GB (1) GB0510770D0 (en)

Similar Documents

Publication Publication Date Title
IL188746A0 (en) Treatment of cancer
ZA200805877B (en) Pyridiazinone derivatives for tumour treatment
EP1814544A4 (en) Cancer treatments
IL186408A0 (en) Combination treatment methods
PL1877096T3 (en) Non-lithotripsic kidney-stone therapy
PT1830847E (en) Treatment for cancer
GB0428187D0 (en) Cancer treatment
GB0504206D0 (en) Combination therapy
GB0509052D0 (en) Combination therapy
GB0413346D0 (en) Treating cancer
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0516068D0 (en) Well treatment
GB0517387D0 (en) Combinations for the treatment of cancer
GB0511769D0 (en) Treatment
GB0525540D0 (en) New treatment
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
GB0520067D0 (en) Treatment of cancer
GB0502171D0 (en) Well treatment
GB0404675D0 (en) Cancer treatment
GB0525535D0 (en) Tumour treatment
GB0507685D0 (en) Cancer treatment
GB0710871D0 (en) Cancer treatment
GB0510770D0 (en) Cancer treatment
GB0505045D0 (en) Cancer treatment
GB0505773D0 (en) Cancer treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)